Folks, do you remember a few years ago, when we caught a glimpse of possible changes to Greg Pugen's WF10 site?
Take a look:
wf10.com
Of all the changes expected at Dimethaid Research, those with respect to knowledge and understanding of WF10 will be the most surprising, IMO.
Klutz once posted on SH:
"What I find most disturbing is that this strategy has been pursued in preference to further development of WF-10, a drug that no insurer will have any difficulty paying for should it prove successful. As DMX should know, time-to-market is everything in the pharma game. Most pharma companies are set up to avoid unnecessary delays because the costs associated with delayed market entry can be truly staggering. It isn't simply a loss of the first few years of sales. It's the difference between what sales are in any given year and what they would have been for that year assuming an earlier launch. The loss is cumulative and compounded over the life cycle of the product. Mathematially it's actually equivalent to the revenue that would have been earned with an extra 2 or 3 years (however long the delay) of patent life. If the drug is a blockbuster you're talking billions in lost revenue. It's a substantial loss even if the drug is an average seller. (Personally I've always thought this delay was the most monumentally stupid decision I have seen in drug development in a long time. It is costing the company and its shareholders far more than they can imagine. Dilution, high interest rates, payments to Provalis -- are chickenfeed compared to what the company has left on the table if WF-10 proves successful.)"
stockhouse.ca
I believe investors who bought into the disinformation which attended management's inability to fund Oxo Chemie's acquisition and WF10's development will be surprised. Anticipated trials for HCV and cancer will begin to reveal a more correct understanding of WF10, and its untapped possibilities.
The combination of WF10, Penecure and Pennsaid will reveal the true potential in Dimethaid Research - badly, but reasonably underestimated - given past management's errors.
JMO.
Jim |
